Total Payments
$3,049
2024 Payments
$149.34
Companies
34
Transactions
192
Medicare Patients
2,404
Medicare Billing
$616,098
Payment Breakdown by Category
Food & Beverage$3,049 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,049 | 192 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Collegium Pharmaceutical, Inc. | $619.23 | 51 | $0 (2022) |
| Scilex Pharmaceuticals Inc. | $288.41 | 15 | $0 (2023) |
| Nevro Corp. | $266.75 | 6 | $0 (2023) |
| Averitas Pharma Inc. | $258.06 | 8 | $0 (2024) |
| PFIZER INC. | $240.70 | 25 | $0 (2019) |
| Daiichi Sankyo Inc. | $205.41 | 13 | $0 (2019) |
| Purdue Pharma L.P. | $130.95 | 13 | $0 (2018) |
| Vertical Pharmaceuticals, LLC | $115.88 | 8 | $0 (2019) |
| Egalet US Inc | $110.36 | 8 | $0 (2018) |
| GRT US Holding, Inc. | $106.69 | 5 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $149.34 | 6 | Averitas Pharma Inc. ($111.22) |
| 2023 | $309.82 | 11 | Averitas Pharma Inc. ($146.84) |
| 2022 | $321.03 | 13 | Nevro Corp. ($98.64) |
| 2021 | $231.58 | 16 | Collegium Pharmaceutical, Inc. ($139.33) |
| 2020 | $392.59 | 19 | Nevro Corp. ($147.58) |
| 2019 | $477.61 | 31 | Collegium Pharmaceutical, Inc. ($127.00) |
| 2018 | $475.97 | 37 | Collegium Pharmaceutical, Inc. ($169.54) |
| 2017 | $690.68 | 59 | PFIZER INC. ($137.68) |
All Payment Transactions
192 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/04/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $26.79 | General |
| Category: PAIN MANAGEMENT | ||||||
| 10/08/2024 | Abbott Laboratories | PROCLAIM (Device) | Food and Beverage | In-kind items and services | $14.96 | General |
| Category: Neuromodulation | ||||||
| 08/19/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $27.66 | General |
| Category: PAIN MANAGEMENT | ||||||
| 05/16/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $27.75 | General |
| Category: PAIN MANAGEMENT | ||||||
| 03/26/2024 | Pacira Pharmaceuticals Incorporated | Exparel (Drug), Iovera, Zilretta | Food and Beverage | In-kind items and services | $23.16 | General |
| Category: Pain Management | ||||||
| 02/09/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $29.02 | General |
| Category: PAIN MANAGEMENT | ||||||
| 10/06/2023 | PROTEGA PHARMACEUTIALS INC | ROXYBOND (Drug) | Food and Beverage | In-kind items and services | $44.85 | General |
| Category: Pain Management | ||||||
| 09/20/2023 | Scilex Pharmaceuticals Inc. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $15.99 | General |
| Category: Analgesic | ||||||
| 08/03/2023 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $26.46 | General |
| Category: PAIN MANAGEMENT | ||||||
| 07/19/2023 | Scilex Pharmaceuticals Inc. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $20.49 | General |
| Category: Analgesic | ||||||
| 04/06/2023 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $62.16 | General |
| Category: PAIN MANAGEMENT | ||||||
| 04/04/2023 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $32.44 | General |
| Category: PAIN MANAGEMENT | ||||||
| 03/23/2023 | Scilex Pharmaceuticals Inc. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $21.19 | General |
| Category: Analgesic | ||||||
| 03/08/2023 | Nevro Corp. | Senza (Device) | Food and Beverage | In-kind items and services | $20.53 | General |
| Category: Spinal Cord Stimulator | ||||||
| 02/21/2023 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $25.78 | General |
| Category: PAIN MANAGEMENT | ||||||
| 02/16/2023 | Scilex Pharmaceuticals Inc. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $21.69 | General |
| Category: Analgesic | ||||||
| 01/09/2023 | IBSA Pharma Inc. | LICART (Drug), TIROSINT, TIROSINT | Food and Beverage | Cash or cash equivalent | $18.24 | General |
| Category: non-opioid analgesic | ||||||
| 12/08/2022 | Scilex Pharmaceuticals Inc. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $15.19 | General |
| Category: Analgesic | ||||||
| 11/23/2022 | Scilex Pharmaceuticals Inc. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $14.53 | General |
| Category: Analgesic | ||||||
| 10/19/2022 | Scilex Pharmaceuticals Inc. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $19.82 | General |
| Category: Analgesic | ||||||
| 09/28/2022 | Nevro Corp. | Omnia (Device) | Food and Beverage | In-kind items and services | $98.64 | General |
| Category: Spinal Cord Stimulator | ||||||
| 09/28/2022 | GRT US Holding, Inc. | Qutenza (Drug) | Food and Beverage | In-kind items and services | $25.59 | General |
| Category: Pain Management | ||||||
| 09/01/2022 | Scilex Pharmaceuticals Inc. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $19.57 | General |
| Category: Analgesic | ||||||
| 07/27/2022 | GRT US Holding, Inc. | Qutenza (Drug) | Food and Beverage | In-kind items and services | $22.77 | General |
| Category: Pain Management | ||||||
| 06/28/2022 | Trevena, Inc. | Olinvyk (Drug) | Food and Beverage | Cash or cash equivalent | $20.54 | General |
| Category: Pain Management | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 487 | 1,072 | $261,790 | $90,029 |
| 2022 | 10 | 611 | 1,974 | $497,465 | $165,707 |
| 2021 | 11 | 663 | 2,175 | $546,645 | $187,421 |
| 2020 | 11 | 643 | 2,148 | $537,870 | $172,941 |
Total Patients
2,404
Total Services
7,369
Medicare Billing
$616,098
Procedure Codes
39
All Medicare Procedures & Services
39 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2023 | 82 | 136 | $65,280 | $26,489 | 40.6% |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2023 | 60 | 67 | $43,550 | $16,213 | 37.2% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2023 | 91 | 218 | $43,600 | $13,276 | 30.5% |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2023 | 59 | 73 | $26,280 | $11,203 | 42.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 90 | 373 | $37,300 | $10,716 | 28.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 83 | 177 | $24,780 | $10,140 | 40.9% |
| 62323 | Injection of substance into lower spine canal using imaging guidance | Facility | 2023 | 22 | 28 | $21,000 | $1,992 | 9.5% |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2022 | 109 | 288 | $187,200 | $69,572 | 37.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 106 | 760 | $67,740 | $28,213 | 41.6% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2022 | 122 | 386 | $77,200 | $23,390 | 30.3% |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2022 | 68 | 89 | $42,720 | $17,676 | 41.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 103 | 267 | $31,940 | $16,202 | 50.7% |
| 62323 | Injection of substance into lower spine canal using imaging guidance | Facility | 2022 | 36 | 49 | $36,750 | $3,814 | 10.4% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2022 | 17 | 65 | $34,400 | $3,689 | 10.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 19 | 19 | $3,985 | $1,506 | 37.8% |
| 62321 | Injection of substance into middle or upper spine canal using imaging guidance | Facility | 2022 | 12 | 19 | $14,250 | $1,484 | 10.4% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2022 | 19 | 32 | $1,280 | $160.05 | 12.5% |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2021 | 109 | 334 | $217,100 | $81,374 | 37.5% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 113 | 811 | $64,880 | $30,205 | 46.6% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2021 | 118 | 459 | $91,800 | $28,043 | 30.5% |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2021 | 75 | 102 | $48,960 | $20,271 | 41.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 110 | 281 | $28,100 | $16,998 | 60.5% |
| 62323 | Injection of substance into spinal canal of lower back or sacrum using imaging guidance | Facility | 2021 | 46 | 62 | $46,500 | $4,706 | 10.1% |
| 62321 | Injection of substance into spinal canal of upper or middle back using imaging guidance | Facility | 2021 | 18 | 26 | $19,500 | $2,002 | 10.3% |
| 20610 | Aspiration and/or injection of large joint or joint capsule | Office | 2021 | 17 | 33 | $17,600 | $1,760 | 10.0% |
About Dr. David Demangone, M.D
Dr. David Demangone, M.D is a Pain Medicine healthcare provider based in Willoughby, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1548225832.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Demangone, M.D has received a total of $3,049 in payments from pharmaceutical and medical device companies, with $149.34 received in 2024. These payments were reported across 192 transactions from 34 companies. The most common payment nature is "Food and Beverage" ($3,049).
As a Medicare-enrolled provider, Demangone has provided services to 2,404 Medicare beneficiaries, totaling 7,369 services with total Medicare billing of $616,098. Data is available for 4 years (2020–2023), covering 39 distinct procedure/service records.
Ad
Practice Information
- Specialty Pain Medicine
- Location Willoughby, OH
- Active Since 04/19/2006
- Last Updated 06/17/2011
- Taxonomy Code 208VP0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1548225832
Products in Payments
- XTAMPZA (Drug) $499.47
- QUTENZA (Drug) $258.06
- LYRICA (Drug) $188.85
- ZTLido (Drug) $187.42
- Senza Spinal Cord Stimulation System (Device) $147.58
- Movantik (Drug) $126.97
- Morphabond ER (Drug) $114.47
- Qutenza (Drug) $106.69
- LORZONE (Drug) $105.01
- ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH (Drug) $100.99
- Omnia (Device) $98.64
- Xtampza ER (Drug) $97.12
- ARYMO ER (Drug) $55.03
- OXYCONTIN (Drug) $53.78
- ZOHYDRO ER (Drug) $47.33
- ROXYBOND (Drug) $44.85
- SPECTRA WAVEWRITER (Device) $42.88
- RELISTOR (Drug) $42.54
- EMBEDA (Drug) $41.86
- BELBUCA (Drug) $41.17
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.